

**Amendments to the Claims**

Please cancel claims 43-47, 49, 50, 53-60.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-50. (Canceled)

51. (Previously presented) A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a  $K_d$  value of no more than about  $1 \times 10^{-8}M$ , said humanized anti-VEGF antibody comprising a heavy chain variable domain sequence of SEQ ID NO:116 and a light chain variable domain sequence of SEQ ID NO:115.

52. (Previously presented) A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a  $K_d$  value of no more than about  $1 \times 10^{-8}M$ , said humanized anti-VEGF antibody comprising a heavy chain variable domain sequence of SEQ ID NO:7 and a light chain variable domain sequence of SEQ ID NO:8.

53.-60. (Canceled)